» Articles » PMID: 33041323

Novel Copper Complex CTB Regulates Methionine Cycle Induced TERT Hypomethylation to Promote HCC Cells Senescence Via Mitochondrial SLC25A26

Overview
Journal Cell Death Dis
Date 2020 Oct 12
PMID 33041323
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Related research has recognized the vital role of methionine cycle metabolism in cancers. However, the role and mechanism of methionine cycle metabolism in hepatocellular carcinoma are still unknown. In this study, we found that [Cu(ttpy-tpp)Br]Br (Referred to as CTB) could induce hepatocellular carcinoma cells senescence, which is a new copper complex synthesized by our research group. Interestingly, CTB induces senescence by inhibiting the methionine cycle metabolism of HCC cells. Furthermore, the inhibitory effect of CTB on the methionine cycle depends on mitochondrial carrier protein SLC25A26, which was also required for CTB-induced HCC cells senescence. Importantly, we found that CTB-induced upregulation of SLC25A26 could cause abnormal methylation of TERT and inhibited TERT expression, which is considered to be an essential cause of cell senescence. The same results were also obtained in vivo, CTB inhibits the growth of subcutaneously implanted tumors in nude mice and promoted the expression of senescence markers in tumor tissues, and interference with SLC25A26 partially offset the antitumor effect of CTB.

Citing Articles

The Role of Mitochondrial Solute Carriers SLC25 in Cancer Metabolic Reprogramming: Current Insights and Future Perspectives.

Ahmed A, Iaconisi G, Di Molfetta D, Coppola V, Caponio A, Singh A Int J Mol Sci. 2025; 26(1.

PMID: 39795950 PMC: 11719790. DOI: 10.3390/ijms26010092.


Cancer Therapeutic Potential and Prognostic Value of the SLC25 Mitochondrial Carrier Family: A Review.

Gao R, Zhou D, Qiu X, Zhang J, Luo D, Yang X Cancer Control. 2024; 31:10732748241287905.

PMID: 39313442 PMC: 11439189. DOI: 10.1177/10732748241287905.


Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma.

Ucdal M, Burus A, Celtikci B Hepatol Forum. 2024; 5(3):150-160.

PMID: 39006147 PMC: 11237245. DOI: 10.14744/hf.2023.2023.0028.


Fresh Insights Into : Potential New Therapeutic Target for Cancers: A Review.

Xu Y, Hong Z, Yu S, Huang R, Li K, Li M Oncol Rev. 2024; 18:1379323.

PMID: 38745827 PMC: 11091378. DOI: 10.3389/or.2024.1379323.


Construction of a Novel Cuproptosis-Related ceRNA Network-SNHG3/miR-1306-5p/PDHA1 and Identification of SNHG3 as a Prognostic Biomarker in Hepatocellular Carcinoma.

Pan Y, Zhang Y, Hu X, Li S ACS Omega. 2023; 8(41):38690-38703.

PMID: 37867671 PMC: 10586270. DOI: 10.1021/acsomega.3c06018.


References
1.
Couri T, Pillai A . Goals and targets for personalized therapy for HCC. Hepatol Int. 2019; 13(2):125-137. DOI: 10.1007/s12072-018-9919-1. View

2.
Faivre S, Rimassa L, Finn R . Molecular therapies for HCC: Looking outside the box. J Hepatol. 2020; 72(2):342-352. DOI: 10.1016/j.jhep.2019.09.010. View

3.
Zhou F, Shang W, Yu X, Tian J . Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2017; 38(2):741-767. DOI: 10.1002/med.21455. View

4.
Yang J, Hainaut P, Gores G, Amadou A, Plymoth A, Roberts L . A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10):589-604. PMC: 6813818. DOI: 10.1038/s41575-019-0186-y. View

5.
De Stefano F, Chacon E, Turcios L, Marti F, Gedaly R . Novel biomarkers in hepatocellular carcinoma. Dig Liver Dis. 2018; 50(11):1115-1123. DOI: 10.1016/j.dld.2018.08.019. View